FearLess in NeuroOncology
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorVirginia Commonwealth University
About this trial
The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers
Eligibility criteria
Qualifiers
Self-report a diagnosis of a primary malignant brain tumor (grade II-IV)
>2 weeks post-cranial resection or biopsy
Elevated Fear of Recurrence Distress Rating
Primarily English speaking
Disqualifiers
Cognitive impairment that might prohibit active intervention engagement
Inability to understand and provide informed consent
Inability to attend virtual sessions due to unstable or no internet connection
Trial design
Treatments tested in this trial
- Fearless in Neuro-Oncology
Treatment groups
112 Participants
are divided into 2 treatment groupsSponsors and collaborators
Virginia Commonwealth University
Lead sponsor
National Cancer Institute (NCI)
Collaborator
National Brain Tumor Society
Collaborator
Source ClinicalTrials.gov